作为胃癌中的瘤抑制剂的PDK4:对代谢调节,免疫调节和预后潜力的影响
Jin Xu1, Jie Sun1, Nannan Zhang1
1Department of Gastroenterology, Jiangsu Province Geriatric Institute, Geriatric Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
酸盐脱酶激酶4 (PDK4) 在胃癌 (GC) 中被下调,作为瘤抑制剂. 恢复PDK4可以通过影响新陈代谢和免疫力来对抗GC进展和耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 胃癌 (GC) 是癌症死亡的主要原因之一.
- 代谢失调越来越多地与GC进展有关.
- 酸盐脱酶激酶4 (PDK4) 是一种关键的代谢调节剂.
研究的目的:
- 在GC中调查PDK4的表达模式.
- 确定PDK4的预后意义.
- 阐明PDK4在GC中的分子相互作用和免疫调节作用.
主要方法:
- 利用TCGA-STAD和GSE54129数据集的综合生物信息学分析.
- 进行了差异性基因表达,通路丰富和网络分析 (PPI,ceRNA).
- 通过生存,考克斯回归和ROC分析评估临床相关性;评估免疫透.
主要成果:
- 在GC组织中,PDK4表达显著下调.
- 高PDK4表达与晚期相关,但预测了有利的预后.
- PDK4影响关键的代谢途径,与B细胞和CD4+T细胞的丰富性有关,具有诊断和预后价值.
结论:
- 在GC中,PDK4充当瘤抑制剂,连接代谢重编程,表观遗传调节和免疫微环境.
- 降低PDK4的调节促进了GC的进展和免疫逃避.
- 恢复PDK4活动是一个潜在的治疗策略,可以对抗GC的攻击性和治疗耐药性.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
相关概念视频
Inhibition of Cdk Activity
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
